1887

Abstract

Introduction. Urinary tract infections (UTIs) remain common infections diagnosed in outpatients as well as hospitalized patients. Community-acquired UTIs are generally caused by Escherichia coli and other members of the family Enterobacteriaceae. Burkholderia cepacia is an opportunistic pathogen mainly affecting immunocompromised and hospitalized patients, particularly those who have received prior broad-spectrum antibacterial therapy.

Case presentation. Urine samples were collected from 157 outpatients clinically diagnosed with UTI and from 100 healthy control subjects. Samples were cultured on differential media and non-motile lactose-non-fermentors were identified via the Remel RapID ONE system. The isolates were tested by the disc diffusion method against 17 antimicrobial agents. Burkholderia was isolated as a single organism from four patients having uncomplicated infections, and one from recurrent infection. None of these patients had an underlying risk factor for this pathogen. Identification of these isolates by the Remel-RapID ONE system was confirmed by recA gene amplification. The four isolates were resistant to lincomycin, nalidixic acid, oxacillin and penicillin G. These cases received monotherapy of oral co-trimoxazole.

Conclusions. Our findings alert urologists and diagnostic laboratories to the potential of B. cepacia complex infections in similar cases, and that this bacterium should not be ruled out.

Loading

Article metrics loading...

/content/journal/jmmcr/10.1099/jmmcr.0.005081
2017-01-31
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jmmcr/4/1/jmmcr005081.html?itemId=/content/journal/jmmcr/10.1099/jmmcr.0.005081&mimeType=html&fmt=ahah

References

  1. Wagenlehner FM, Hoyme U, Kaase M, Fünfstück R, Naber KG et al. Uncomplicated urinary tract infections. Dtsch Arztebl Int 2011;108:415–423 [CrossRef][PubMed]
    [Google Scholar]
  2. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Dis Mon 2003;49:71–82 [CrossRef][PubMed]
    [Google Scholar]
  3. Bahadin J, Teo SH, Mathew S. Aetiology of community-acquired urinary tract infection and antimicrobial susceptibility patterns of uropathogens isolated. Singapore Med J 2011;52:415–420[PubMed]
    [Google Scholar]
  4. Horcajada JP, Shaw E, Padilla B, Pintado V, Calbo E et al. Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clin Microbiol Infect 2013;19:962–968 [CrossRef][PubMed]
    [Google Scholar]
  5. Li FK, Chan KW, Chan TM, Lai KN. Burkholderia urinary tract infection after renal transplantation. Transpl Infect Dis 2003;5:59–61[PubMed][CrossRef]
    [Google Scholar]
  6. Zeeshan M, Aziz T, Naqvi F. Recurrent urinary tract infection by Burkholderia cepacia in a live related renal transplant recipient. J Pak Med Assoc 2012;62:496–498[PubMed]
    [Google Scholar]
  7. Lee KW, Lee SK, Cho H. Burkholderia cepacia causing nosocomial urinary tract infection in children. Child Kidney Dis 2015;19:143–147[CrossRef]
    [Google Scholar]
  8. Wilson ML, Gaido L. Laboratory diagnosis of urinary tract infections in adult patients. Clin Infect Dis 2004;38:1150–1158 [CrossRef][PubMed]
    [Google Scholar]
  9. Alós JI. Epidemiology and etiology of urinary tract infections in the community. Antimicrobial susceptibility of the main pathogens and clinical significance of resistance. Enferm Infecc Microbiol Clin 2005;23:3–8[PubMed][CrossRef]
    [Google Scholar]
  10. Mahenthiralingam E, Bischof J, Byrne SK, Radomski C, Davies JE et al. DNA-based diagnostic approaches for identification of burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J Clin Microbiol 2000;38:3165–3173[PubMed]
    [Google Scholar]
  11. Khatri B, Basnyat S, Karki A, Poudel A, Shrestha B. Etiology and antimicrobial susceptibility pattern of bacterial pathogens from urinary tract infection. Nepal Med Coll J 2012;14:129–132[PubMed]
    [Google Scholar]
  12. van Pelt C, Verduin CM, Goessens WH, Vos MC, Tümmler B et al. Identification of Burkholderia spp. in the clinical microbiology laboratory: comparison of conventional and molecular methods. J Clin Microbiol 1999;37:2158–2164[PubMed]
    [Google Scholar]
  13. Gautam V, Singhal L, Ray P. Burkholderia cepacia complex: beyond Pseudomonas and Acinetobacter. Indian J Med Microbiol 2011;29:4–12 [CrossRef][PubMed]
    [Google Scholar]
  14. Roberts JB, Speller DC. Letter: Pseudomonas cepacia in renal calculi. Lancet 1973;2:1099[PubMed][CrossRef]
    [Google Scholar]
  15. Shehabi AA, Abu-Al-Soud W, Mahafzah A, Khuri-Bulos N, Abu Khader I et al. Investigation of Burkholderia cepacia nosocomial outbreak with high fatality in patients suffering from diseases other than cystic fibrosis. Scand J Infect Dis 2004;36:174–178 [CrossRef][PubMed]
    [Google Scholar]
  16. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000;161:1206–1212 [CrossRef][PubMed]
    [Google Scholar]
  17. Zhou J, Chen Y, Tabibi S, Alba L, Garber E et al. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2007;51:1085–1088 [CrossRef][PubMed]
    [Google Scholar]
  18. Moss RB. Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Clin Infect Dis 1995;21:839–849[PubMed][CrossRef]
    [Google Scholar]
  19. Burns JL, Lien DM, Hedin LA. Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant Pseudomonas cepacia. Antimicrob Agents Chemother 1989;33:1247–1251[PubMed][CrossRef]
    [Google Scholar]
  20. Abbo LM, Hooton TM. Antimicrobial stewardship and urinary tract infections. Antibiotics 2014;3:174–192 [CrossRef][PubMed]
    [Google Scholar]
  21. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement, M100-S22:32 Wayne, PA, USA: CLSI; 2012
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmmcr/10.1099/jmmcr.0.005081
Loading
/content/journal/jmmcr/10.1099/jmmcr.0.005081
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error